Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial

Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes

(2018) Carlo Bruno Giorda et al.   ACTA DIABETOLOGICA

Diabetic Cardiomyopathy

(2018) Guanghong Jia et al.   CIRCULATION RESEARCH

Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction

(2018) Peder L. Myhre et al.   Circulation-Heart Failure

Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study

(2017) Gina LaRocca et al.   EUROPEAN HEART JOURNAL

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure

(2017) Abhinav Sharma et al.   EUROPEAN JOURNAL OF HEART FAILURE

Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation

(2017) Simon de Denus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction

(2017) Inder S. Anand et al.   JACC-Heart Failure

Impact of diabetes on the predictive value of heart failure biomarkers

(2016) Nuria Alonso et al.   Cardiovascular Diabetology

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

(2016) Søren L. Kristensen et al.   Circulation-Heart Failure

Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin

(2015) M. R. Zile et al.   CIRCULATION

Identifying Novel Biomarkers for Cardiovascular Events or Death in People With DysglycemiaClinical Perspective

(2015) Hertzel C. Gerstein et al.   CIRCULATION

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

(2015) Anoop Dinesh Shah et al.   Lancet Diabetes & Endocrinology

Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial

(2014) Frank Edelmann et al.   EUROPEAN JOURNAL OF HEART FAILURE

Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction

(2014) Robert J. Mentz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Spironolactone for Heart Failure with Preserved Ejection Fraction

(2014) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

(2013) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

(2011) Akshay S. Desai et al.   AMERICAN HEART JOURNAL

Usefulness of Plasma Galectin-3 Levels in Systolic Heart Failure to Predict Renal Insufficiency and Survival

(2011) W.H. Wilson Tang et al.   AMERICAN JOURNAL OF CARDIOLOGY

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial

(2011) Natalia Lopez-Andrès et al.   EUROPEAN JOURNAL OF HEART FAILURE

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover

(2009) Ramón Martos et al.   EUROPEAN JOURNAL OF HEART FAILURE